Wasabi Surveillance Cloud Delivers ‘Bottomless’ Storage to Support the Massive Growth of Video in the Surveillance Industry
Wasabi Technologies, the hot cloud storage company, today introduced Wasabi Surveillance Cloud, a first-of-its-kind solution that enables organizations to offload video surveillance footage from their local storage environment directly to the cloud without ever running out of capacity. This ‘bottomless’ approach to video storage is vital for the surveillance industry that is currently struggling to manage enormous amounts of video in high resolution environments, increasingly large file sizes, stringent regulatory and retention requirements, and business and analytics applications tied to surveillance.
IDC’s Video Surveillance Survey 2022 shows a growing number of enterprises expect their video surveillance storage requirements will increase over the next three years.1 However the cost of updating an existing technology stack to meet these new demands is simply prohibitive. “Enterprises increasingly recognize the cost savings, agility, and video data accessibility that cloud storage provides, but they need a way to maintain the benefits of their existing technology stack as well,” said Mike Jude, research director, video surveillance & vision applications, IDC. “It is essential that storage architecture meet the holistic requirements of modern surveillance in a way that is cost-effective.”
Wasabi Surveillance Cloud addresses these challenges head on by creating a seamless hybrid storage environment that preserves current on-site technology investments and maximizes their ROI without sacrificing any of the benefits. Users of every major video management system (VMS) can offload infrequently accessed video from their on-site servers directly to Wasabi hot cloud storage, which is much more affordable than cloud vendors like AWS S3, Google, or Microsoft Azure with no fees for egress or API requests. The video data is kept ‘hot’ so it’s always available and retrievable within milliseconds. With Wasabi Surveillance Cloud, a once siloed VMS technology instantly becomes cloud-aware, providing a simple and seamless transition to utilizing cloud storage.
Key benefits of Wasabi Surveillance Cloud include:
- Seamless integration with all major VMS providers
- Industry-leading protection with immutability to mitigate ransomware or accidental deletions
- Restoration of video and data directly from the cloud
- Ability to scale on-demand, avoiding costly server upgrades while increasing resolution and frame rate
- Compliance with major industry and government regulations and retention requirements, including HIPAA, CJIS, FERPA, FINRA, and more
- Deployed globally in top-tier data centers certified for SOC 2, ISO 27001 and PCI-DSS
“Many organizations make significant technology investments for video surveillance, but often the video and data storage architecture is put under immense pressure,” said David Boland, vice president of cloud strategy, Wasabi Technologies. “Wasabi Surveillance Cloud allows the industry to take advantage of the best of cloud and on-premises for a truly ‘bottomless storage’ solution that supports the exponential growth of video data.”
For more information on Wasabi Surveillance Cloud, visit https://wasabi.com/cloud-storage-for-surveillance/.
Attending ISC West? Visit Wasabi at Booth #2077 for a demo of Wasabi Surveillance Cloud and to speak with our surveillance experts.
About Wasabi Technologies
Wasabi provides simple, predictable and affordable hot cloud storage for businesses all over the world. It enables organizations to store and instantly access an unlimited amount of data at 1/5th the price of the competition with no complex tiers or unpredictable egress fees. Trusted by tens of thousands of customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.
Follow and connect with Wasabi on LinkedIn, Twitter, Facebook, Instagram, and The Bucket.
1 Source: IDC Market Note, Growth of Video Data Expected to Drive Both On- and Off-Premises Storage Infrastructure Growth, doc #US49354822, July 2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005082/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom